MedTrace Logo

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

NCT06762808 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-08-15

No results posted yet for this study

Summary

A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.

Conditions

Interventions

DRUG

Atezolizumab

Given by IV infusion

DRUG

Talazoparib

Given by IV infusion

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Strategic Alliance

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Emma Holliday, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-08-08
Completion
2025-08-08
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06762808 on ClinicalTrials.gov